Quantbot Technologies LP bought a new stake in DBV Technologies SA – (NASDAQ:DBVT) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,463 shares of the company’s stock, valued at approximately $146,000.

A number of other large investors have also recently added to or reduced their stakes in DBVT. Janus Henderson Group PLC purchased a new position in DBV Technologies in the 2nd quarter valued at about $90,724,000. Jennison Associates LLC lifted its holdings in DBV Technologies by 86.4% in the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock valued at $35,784,000 after purchasing an additional 464,341 shares in the last quarter. Botty Investors LLC purchased a new position in DBV Technologies in the 2nd quarter valued at about $2,231,000. Sectoral Asset Management Inc lifted its holdings in DBV Technologies by 34.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock valued at $6,398,000 after purchasing an additional 45,653 shares in the last quarter. Finally, Sabby Management LLC purchased a new position in DBV Technologies in the 2nd quarter valued at about $1,339,000. Institutional investors own 46.94% of the company’s stock.

A number of research firms have issued reports on DBVT. Societe Generale lowered shares of DBV Technologies from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Zacks Investment Research lowered shares of DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 29th. Jefferies Group restated a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. JMP Securities assumed coverage on shares of DBV Technologies in a report on Friday, November 17th. They issued an “outperform” rating on the stock. Finally, Barclays cut their price objective on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $49.63.

DBV Technologies SA – (NASDAQ DBVT) opened at $22.22 on Friday. DBV Technologies SA – has a 1-year low of $21.51 and a 1-year high of $50.57.

COPYRIGHT VIOLATION NOTICE: “Quantbot Technologies LP Buys Shares of 3,463 DBV Technologies SA – (DBVT)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/quantbot-technologies-lp-buys-shares-of-3463-dbv-technologies-sa-dbvt.html.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies SA – (NASDAQ:DBVT).

Institutional Ownership by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related stocks with our FREE daily email newsletter.